
Bilhi Genetics identifies genetic variants that influence susceptibility or resistance to fibrotic and other diseases to enable better prevention, diagnosis, and therapies. The company combines medical genetics expertise with population-based genomics, analyzing DNA, RNA, plasma and clinical data from tens of thousands of samples collected in collaboration with local institutions and communities. It uses AI and state-of-the-art genomic analytics to discover disease-associated variants and biological mechanisms. Bilhi operates as a biotech research organization working with academic, clinical and industry partners to build a representative human genetics dataset for translational research and product development.

Bilhi Genetics identifies genetic variants that influence susceptibility or resistance to fibrotic and other diseases to enable better prevention, diagnosis, and therapies. The company combines medical genetics expertise with population-based genomics, analyzing DNA, RNA, plasma and clinical data from tens of thousands of samples collected in collaboration with local institutions and communities. It uses AI and state-of-the-art genomic analytics to discover disease-associated variants and biological mechanisms. Bilhi operates as a biotech research organization working with academic, clinical and industry partners to build a representative human genetics dataset for translational research and product development.
Headquarters: Marseille, France
Founded: 2011
Focus: Genetic prediction for fibrotic diseases and oncology using genomics and AI
Team size (reported): 2–10 employees
Notable funding: Seed round reported ~€1.35M (Feb 2016)
Genetic prediction and biomarker discovery for fibrotic diseases and oncology
2011
Biotechnology
€1.35M (reported)
Dealroom entry reports a seed round in Feb 2016
Early-stage entries reported around 2011–2012 with SATT Sud-Est involvement